An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
2022 · Nature Microbiology · 99 citations
https://doi.org/10.1038/s41564-022-01119-7
B
Baoxue Quan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
11
Papers
641
Citations
4
h-index
4
i10-index
Baoxue Quan is an academic researcher from Yingkou Institute of Technology. The author has contributed to research in topics: Computational Drug Discovery Methods & SARS-CoV-2 and COVID-19 Research & Power System Optimization and Stability. The author has an h-index of 4, co-authored 10 publications.
ORCID: 0000-0002-7312-2645Papers by this author
worksA new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
2023 · Signal Transduction and Targeted Therapy · 79 citations
https://doi.org/10.1038/s41392-023-01392-w
Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease
2023 · European Journal of Medicinal Chemistry · 15 citations
https://doi.org/10.1016/j.ejmech.2023.115657
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat